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Abstract  
Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and 
severe metabolic disease in many cases. Missense mutations in PPARG are present in ~1:500 
people. Whilst mutations are often binarily classified as ‘benign’ or ‘deleterious’, prospective 
functional classification of all missense PPARG variants suggests that their impact is graded. 
Furthermore, in testing novel mutations with both prototypic ‘endogenous’ (e.g. prostaglandin J2 
(PGJ2)) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic 
agonists selectively rescue function of some PPARg mutants. Here, we report FPLD3 patients, 
harbouring two such PPARg mutations (R308P, A261E). Both PPARg mutants exhibit negligible 
constitutive or PGJ2-induced transcriptional activity but respond readily to synthetic agonists in 
vitro, with structural modelling providing a basis for such differential ligand-dependent 
responsiveness. Concordant with this, dramatic clinical improvement was seen following 
pioglitazone treatment of the patient with R308P mutant PPARg. A patient with A261E mutant 
PPARg also responded beneficially to rosiglitazone, though cardiomyopathy precluded prolonged 
thiazolidinedione use. These observations indicate that detailed structural and functional 
classification can be used to inform therapeutic decisions in patients with PPARG mutations.  
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Peroxisome proliferator-activated receptor gamma (PPARg) is a nuclear receptor originally 
identified in adipocytes (1). Although widely expressed, cell-based, loss-of-function studies clearly 
attest to its primary role in regulating adipogenesis and adipocyte function, with rodent knockout 
studies robustly corroborating these data (2,3). Heterozygous, dominant negative, loss-of-function 
mutations in human PPARG were first described in 1999 (4) with subsequent identification of many 
more receptor defects (5–9). Clinical findings in such cases have refined the phenotype, now known 
as familial partial lipodystrophy type 3 (FPLD3), characterised by a paucity of limb fat, preserved 
abdominal fat, insulin resistant diabetes, dyslipidaemia with particularly labile, diet-sensitive, 
hypertriglyceridaemia, polycystic ovarian syndrome and hypertension.  
 
Like many nuclear receptors PPARg has an amino-terminal activation domain (AF1), a central 
DNA-binding domain (DBD) and a carboxy-terminal ligand-binding domain (LBD). 
PPARg heterodimerises with retinoid X receptor alpha (RXR) and transcriptional activation is 
triggered by ligand-binding, resulting in the release of a corepressor complex and recruitment of a 
coactivator complex. Fatty acids and eicosanoids can activate PPARg, with PGJ2 considered 
prototypic of such putative endogenous PPARg ligands (10-11). Indeed, structural studies suggest 
that the ligand binding pocket of PPARg is ‘promiscuous’ and can accommodate several different 
fatty acids (3). Thiazolidinediones (TZDs), a class of synthetic PPARg agonists, promote 
adipogenesis and improve insulin sensitivity, underpinning their therapeutic use as insulin 
sensitizers in patients with T2DM (12).   
 
The fact that as many as 1:500 people may have missense mutations in PPARG recently prompted 
Majithia et al (7) to generate and functionally characterise all possible missense PPARG mutations, 
to expedite clinical interpretation of the growing number of missense variants identified in patients. 
This resource should aid prompt functional classification of novel PPARG variants. For individuals 
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with established loss-of-function mutations and disease phenotype, therapeutic possibilities are 
limited. Current options include strict dietary fat and calorie restriction, metformin, insulin, GLP1 
agonists and leptin has been tried in patients with very low leptin levels (13). Isolated reports of 
TZD use also exist (9,14-15) but responses were variable (summarised in Supplementary Table 1).  
 
In characterising the properties of all possible PPARG missense mutations (7) we were struck by 
two observations. First, the spectrum of functional scores exhibited by the range of all missense 
PPARG variants suggested that even mutations associated with a monogenic disease are likely to 
perturb protein function to a variable degree, predisposing to a similarly variable phenotype, rather 
than fitting an arbitrary designation as disease-causing or benign. Such gradation of PPARg 
dysfunction is also likely to translate into differential, graded responses to metabolic stress, and to 
molecularly-targeted therapeutic interventions. Second, we noted that a few variants, like R308P, 
manifested a clearly abnormal transcriptional response to prototypic ‘natural’ ligand (e.g. PGJ2), 
whereas their function when tested with a synthetic agonist was near normal (7). These in vitro 
observations suggested that patients harbouring such receptor mutants might respond to treatment 
with synthetic PPARg agonists. Here, we report the dramatic clinical response of a patient, 
harbouring the R308P PPARg variant, following treatment with rosiglitazone. We also describe a 
further novel A261E PPARg mutation, present in two apparently unrelated families, with similarly 
discordant responses to PGJ2 versus synthetic PPARg agonists.  
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Research design and methods 
Participants provided informed written consent and investigations were approved by local research 
ethics committees and conducted in accordance with the Declaration of Helsinki.  
Assessing transcriptional activity of PPARg mutants 
Characterisation of transcriptional activity of PPARg variants was undertaken as described 
previously (16). In brief, 293EBNA cells, cultured in DMEM/10%FCS were transfected with 
Lipofectamine2000 in 96-well plates and assayed for luciferase and β-galactosidase activity 
following a 36-hour incubation with or without ligand with results representing the mean +/- SEM 
of at least three independent experiments in triplicate. 
Structural modelling of PPARg mutants 
Crystallographic modelling of PPARg mutants was undertaken using PPARg structures (1PRG, 
2PRG, 1FM9, 2ZK1, 3DZY, 2XKW) with different ligands, with results illustrated using 
MacPyMOL (Molecular Graphics System, Schrödinger, LLC). 
 
Further methodological details are available in the supplementary material. 
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Results 
Identification of PPARG mutations. Two different heterozygous missense mutations in the ligand 
binding pocket of PPARg were identified in patients presenting with typical features of FPLD3; an 
Arg308Pro (R308P) mutation was detected in a New Zealand woman, and an Ala261Glu (A261E) 
mutation was identified in two unrelated women from South Africa (see supplementary material for 
further clinical details and Table 1 for biochemical results).  
 
Functional studies of PPARg mutants. Both Arginine 308 and Alanine 261 in PPARg are highly 
conserved (Figure 1A). In transfection assays using reporter constructs containing either synthetic 
{(PPARE)3TK-LUC} or natural (human FABP4-LUC) enhancer/promoter elements, both R308P 
and A261E mutants exhibited negligible basal transcriptional activity and minimal responsiveness 
with PGJ2 (Figure 1B, C). However, moderate (100nM farglitazar) or higher concentrations (1µM 
rosiglitazone; 10µM pioglitazone) of synthetic agonists restored  transcriptional activity comparable 
to wild type receptor (Figure 1B, C). Interestingly, the R308P variant returned an intermediate, non-
diagnostic, functional score when tested in a high-throughput cellular assay (Majithia et al (7); Table 
1), reflecting a similar discordance between failure to respond to PGJ2 and activation with 
rosiglitazone. These results suggest that the R308P mutant is transcriptionally resistant to both 
natural ligands present endogenously within transfected cells and PGJ2, with such loss-of-function 
likely contributing to the patient’s lipodystrophic phenotype. 
 
Structural modelling. In the crystal structure of the PPARg LBD, Ala261 and Arg308 are situated 
on different sides of the ligand binding pocket (Figure 2A). Arg308, located close to the amino 
terminus of helix 3 (Figure 2A, B), participates in an extensive hydrogen-bond network (Figure 2D-
F) involving E287 in helix 2 and residues in the loop between helix 2-3. In the unliganded receptor, 
R308 also makes hydrogen bonds within helix 3 (Figure 2D). Upon ligand binding the loop between 
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helix 2-3 adopts varying conformations, depending on the nature of the ligand (Supplementary 
Figure 1). Mutation R308P would completely disrupt both the intra and inter-helical hydrogen bond 
networks (Figure 2G). While PGJ2 does not alter the structural architecture of this region (Figure 
2H); binding of farglitazar, rosiglitazone and pioglitazone can potentially alter the conformation of 
the loop between helix 2-3, thereby providing a mechanism that counteracts the destabilising effect 
of the R308P mutation, preserving transcriptional responsiveness to these synthetic ligands (Figure 
2F,I; Supplementary figure 1B,C,D). In keeping with this prediction, proton nuclear magnetic 
resonance (NMR) spectral analysis confirmed that pioglitazone can bind effectively to the R308P 
mutant (Supplementary figure 2). 
 
Ala261 is located in helix 2a (Figure 2A-C) and the size and charge difference of the A261E 
mutation will cause displacement of helix 2a and the loop to helix 2b, thereby destabilizing the 
ligand binding pocket. This was confirmed using circular dichroism (CD) studies showing a lower 
thermal denaturation temperature compared to the wild type receptor (Supplementary Table 1). As 
PGJ2 docks in this part of the ligand binding cavity, its binding to receptor is expected to be impaired 
(Figure 2C). In contrast, receptor occupancy by rosiglitazone, farglitazar and pioglitazone is not 
structurally dependent on this region, correlating with preservation of transcriptional activation of 
the A261E mutant (Figure 2B, Supplementary figure 1). 
 
Responses to thiazolidinedione therapy.  The R308P proband had previously been treated with 
dietary advice and metformin, but her metabolic control remained suboptimal, so pioglitazone 
30mg/day was commenced, resulting in dramatic improvements in glycaemic control and 
dyslipidaemia (Table 2). Her hirsutism, hyperandrogenism and acanthosis nigricans also improved. 
These changes were largely sustained over a 3-year period without a substantial change in BMI 
(23.7 kg/m² to 22.0 kg/m² at 12 months and 23.0 kg/m² at 24 months).  
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One of the A261E patients was twice treated with rosiglitazone (4 mg twice daily) when her 
glycaemic and triglyceride control deteriorated significantly. On each occasion, this intervention 
was accompanied by substantial falls in her HBA1c as well as improvements in fasting triglyceride 
levels, though these remained labile (Supplementary figure 3). However, therapy was discontinued 
because it exacerbated her severe congestive cardiac failure which ultimately caused her death at 
age 26 years.  
 
Discussion 
The remarkable increase in access to and use of next generation sequencing has accelerated 
discovery of novel Mendelian disorders and detection of mutations in genes known to cause 
monogenic disorders like FPLD3, where ~1:500 people harbour missense mutations (7). Whilst 
most are ‘benign’ or mild in their impact others are pathogenic, but likely in a graded rather than 
binary categorical fashion. As synthetic PPARg ligands are licensed treatments and given the 
severity of the metabolic complications seen in FPLD3 patients, TZDs are obvious therapeutic 
options. Theoretically, FPLD3 patients could be (a) resistant to TZDs due to the extreme 
deleteriousness of the underlying PPARg defect, or (b) responsive to therapy with mutations that 
are unresponsive to low-affinity, endogenous ligands yet activated by higher-affinity synthetic 
agonists, or (c) potentially ‘hyper-responsive’ to specific “designer” ligands that can overcome the 
molecular defect that is particular to a specific receptor mutation.  
 
Here, we report two FPLD3-associated PPARg mutations (A261E, R308P), whose properties fall 
into the latter categories (b,c above). Despite its transcriptional efficacy with wild type PPARg, 
PGJ2, a ligand which is prototypic of the various, endogenous fatty acid and eicosanoid PPARg 
activators, was unable to fully activate transcription mediated by A261E or R308P mutants (Figure 
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1B), whereas exposure to high affinity, synthetic ligands like rosiglitazone, pioglitazone and 
farglitazar achieved full transcriptional activity. Crystal structures of PPARg bound to either 
farglitazar, rosiglitazone, pioglitazone or PGJ2 show differences between these ligands in the nature 
of their occupancy of the binding cavity (Supplementary Figure 1) and structural modelling provides 
a plausible basis for differential mutant PPARg responses to prototypic endogenous versus synthetic 
ligands. Whilst synthetic agonists do not occupy the region of the pocket where A261 is situated, 
this residue is in close proximity to the location of PGJ2, and other fatty acid ligands (16). Modelling 
of the A261E mutation suggests that the alanine to glutamic acid change is likely to perturb PGJ2 
binding directly via steric hindrance, whereas receptor interaction with rosiglitazone, pioglitazone 
and farglitazar would be preserved; correlating with the observed transcriptional responses (Figure 
1B-C). 
 
The R308P mutation involves a different part of the ligand binding cavity and this residue does not 
make direct contact with ligands. Structural modelling suggests that the Arginine to Proline change 
would disrupt local hydrogen bond networks, with deleterious conformational consequences 
affecting transcriptional function of the receptor. Rosiglitazone, pioglitazone and farglitazar (but 
not PGJ2), bind in proximity to R308, possibly stabilising receptor structure. In particular, 
pioglitazone, which we have shown binds effectively to the R308P mutant receptor, makes a 
hydrogen bond with E287 in helix 2, as does R308, counteracting the effect of the R308P mutation 
which is predicted to disrupt this interaction (Figure 2F-I).  
 
In vitro studies with R308P mutant PPARg mirrored her dramatic and sustained response to 
pioglitazone therapy. Thus, her case highlights the importance of recognizing and then establishing 
the genetic basis for severe, early-onset, metabolic disease. Identification of a PPARG mutation 
enabled early treatment with pioglitazone in preference to other standard glucose-lowering 
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therapies, resulting in substantial clinical improvements in all metabolic abnormalities paralleled by 
specific redistribution of body fat, away from visceral and with expansion of subcutaneous depots. 
Moreover, structural modelling and verification with studies of mutant receptor function in vitro, 
provide a plausible explanation for in vivo observations. Specifically, impaired receptor activation 
by endogenous ligands presumably mediates diminished adipogenesis and the FPLD3 phenotype; 
the subsequent profound therapeutic response to pioglitazone likely reflects the ability of this 
synthetic agonist to bypass or overcome the molecular consequences of this mutation. In patients 
harbouring A261E mutant PPARg, we have documented similar, discordant, transcriptional 
responses to prototypic endogenous ligand versus synthetic agonists. We have shown that this 
translates into a beneficial therapeutic response to rosiglitazone in one patient with this receptor 
defect.  
Although our observations are based on prismatic case studies, they are supported by structural 
analyses of the other isolated reports of TZD use in FPLD3 patients (Supplementary table 1); such 
concordance between structural modelling of PPARg mutations, transcriptional responses of mutant 
PPARg to ligands in vitro, and clinical responses to treatment with synthetic agonists in vivo, 
highlight the potential for this approach to inform individualised therapeutic choices. 
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Tables  
 
Table 1. Biochemical findings in probands with FPLD3.  
PPARG mutation Arg308Pro Proband 1 
Ala261Glu 
Proband 2 
Ala261Glu 
Proband 3 
Normal 
range 
Gender Female Female Female  
Age at time of assessment- years 16 22 39  
Age at first presentation- years 16 20 30  
     
Height – m 1.46 1.53 1.45  
Weight – kg 48.0 61.0 55.0  
BMI* - kg/m2 23 26 26  
Total body fat- % 20 NA NA  
Predicted body fat - %** 27 NA NA  
Truncal fat - % 22 NA NA  
Leg fat - % 18 NA NA  
     
Hypertension No No Yes  
T2DM or IGT¶ Yes Yes Yes  
PCOS§ Yes Yes Yes  
NAFLD♯ Yes  NA NA  
     
Triglyceride - mmol/L 13.0 16.6 11.3 <1.7 
HDL-Cholesterol - mmol/L 0.4 0.5 0.5 >1.0 
Total-Cholesterol - mmol/L 4.7 8.2 5.1 <5.1 
     
Insulin - pmol/L 405 1253 NA <60 
Glucose - mU/L 22.4 6.4 12.3 <6.1 
Glycated hemoglobin -mmol/mol 61 NA 78 20-40 
 
     
ALT U/L  20 9 <30 
GGT U/L  32 18 <35 
     
Familial co-segregation 
Unaffected 
mother and 
sibling are 
mutation 
negative 
Affected male 
sibling with the 
mutation. 
Affected male 
sibling with the 
mutation. 
 
***Functional score -0.932 -3.798 -3.798  
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NA denotes not available. Fat mass and distribution was assessed with dual energy X-ray absorptiometry 
(DXA) performed using a GE-lunar iDXA (software version 15). 
*The body-mass index (BMI) is the weight in kilograms divided by the square 
of the height in meters. 
**Predicted body fat = (1.48*BMI)-7 
¶Type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) – yes or no indicates the presence 
or absence of either of these conditions. 
§Polycystic ovary syndrome (PCOS) - yes or no indicates the presence or absence of this syndrome. 
♯Non-alcoholic fatty liver disease (NAFLD) – yes indicates NAFLD as confirmed by ultrasound and 
magnetic resonance spectroscopy. 
***Functional score as derived from http://miter.broadinstitute.org/ 		 	
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Table	2.	Comparison	of	investigations	before	and	following	Pioglitazone	treatment.		
Investigations Before 
treatment 
At 12 month 
treatment 
At 24 month 
treatment 
Reference 
range 
Weight (kg) 
 
Diabetes profile  
49.0 48.6 50.5 
 
HBA1c (mmol/mol ) 61 42 31 20 - 40 
Glucose (mmol/L) 12.0 4.0 3.7 < 6.1 
Insulin (pmol/L) 405 ND* ND* 10 -60 
     
Liver enzymes     
ALT(IU/L) 64 35 33 < 30 
GGT(IU/L) 34 16 15 < 35 
 
Hormonal profile 
    
Free Testosterone 
(pmol/L) 
198 84 ND* < 50 
SHBG(nmol/L) 16 14 ND* 20 - 90 
Free Androgen Index 450 214 ND* < 80 
FSH (IU/L)# 8.8 4.5 7.1 3 - 25 
LH (IU/L)# 14.8 
 
4.3 5.1 2.0 - 25 
Lipid profile      
TG (mmol/L) 13.2 2.4 1.6 < 1.7 
HDL (mmol/L) 0.4 0.6 0.7 > 1.0 
Total Cholesterol 
(mmol/L) 
4.7 3 3.8 < 5.1 
LDL(mmol/L) 2 1.3 2.4 < 3.4 	ND*:	not	done;	#	FSH:	Follicle	stimulating	hormone;	LH:	Luteinizing	hormone;	LDL:	Low	density	lipids	HDL:	High	density	Lipids;	TG:	Triglyceride					
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Figure legends 
 
1A. Schematic representation of the three major domains of PPARg, showing the locations of the 
two mutations and the conservation of the mutated residues between species (A261, R308 – PPARγ2 
nomenclature). 
 
1B. Transcriptional responses of empty vector (pcDNA), R308P or A261E mutant PPARg2 to PGJ2 
and Rosiglitazone, Pioglitazone and Farglitazar (doses in nM on x-axis) when tested with a 
(PPARE)3TKLUC reporter construct and Bos-β-gal internal control plasmid. Results are expressed 
as a percentage of the maximum activation achieved with wild type (WT) PPARg2 and represent 
the mean ± SEM of at least three independent experiments in triplicate. 
 
1C.Transcriptional responses of empty vector (pcDNA), R308P or A261E mutant PPARg2 to PGJ2 
and Rosiglitazone, Pioglitazone and Farglitazar (doses in nM on x-axis) when tested with a 
hFABP4-Luc reporter construct and Bos-β-gal internal control plasmid. Results are expressed as a 
percentage of the maximum activation achieved with wild type (WT) PPARg2 and represent the 
mean ± SEM of at least three independent experiments in triplicate. 
 
2. A-I. Crystallographic modelling based on structures of unliganded PPARg (1PRG) or bound to 
PGJ2 (2ZK1) or pioglitazone (2XKW). One mutated residue (A261) is in the proximity of PGJ2 
(A) whereas the other amino acid (R308) is in the vicinity of pioglitazone (B). Substitution of 
glutamic acid for alanine at residue 261 (A261E) can interfere with PGJ2 binding via steric 
hindrance (C). The side-chain of arginine 308 (R308) participates in a network of intrahelical (H3) 
and interhelical (e.g. E287 in H2) hydrogen bonds in unliganded (D) and liganded (E,F) PPARg. 
Mutation of this residue to Proline likely disrupts this hydrogen bond network (G). PGJ2, which 
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binds elsewhere in the ligand binding cavity, is unable to prevent loss of such interactions (H), 
whereas pioglitazone, which binds in the vicinity, hydrogen bonds with E287 and could preserve 
receptor conformation (I). H, helix. 
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